Evidence map›Paper›PMID 22614103›Full record

ArticleMolecular medicine reports2012

Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.

Kazuyuki Imakiire, Hirofumi Uto, Yuko Sato, Fumisato Sasaki, Seiichi Mawatari, Akio Ido, Kazuya Shimoda, Katsuhiro Hayashi, Sherri O Stuver, Yoshito Ito and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Hepatic pathological features in naïve patients with chronic hepatitis C who have developed thyroid disorder.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Kazuyuki ImakiireDigestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Hirofumi Uto
Yuko Sato
Fumisato Sasaki
Seiichi Mawatari
Akio Ido
Kazuya Shimoda
Katsuhiro Hayashi
Sherri O Stuver
Yoshito Ito
Takeshi Okanoue
Hirohito Tsubouchi
Kagoshima University · JP

Funding

HCV Infection--Risk Factors for ProgressionR01CA087982 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI STUVER, SHERRI O · 2001 to 2005
$2.9M
NCI NIH HHS CA87982NCI NIH HHS R01 CA087982
6 · The paper itself

Abstract

Certain hepatitis C virus (HCV) carriers exhibit persistently normal alanine aminotransferase (ALT) levels (PNALT) (≤ 30 IU/l) accompanied by normal platelet counts (≥ 15 x 10(4)/µl); these individuals show milder disease activity and slower progression to cirrhosis. This study aimed to elucidate the characteristics of HCV carriers with PNALT using serum proteomics. The first group of subjects, who underwent clinical evaluation in the hospital, consisted of 19 HCV carriers with PNALT (PNALT-1) and 20 chronic hepatitis C (CHC-1) patients. The second group of subjects was part of a cohort study on the natural history of liver disease, and included 37 PNALT (PNALT-2) and 30 CHC (CHC-2) patients. Affinity bead-purified serum protein was subjected to matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis. Serum proteomics showed that 6 protein peaks with mass-to-charge ratios ranging from 1,000 to 3,000 differed significantly between the PNALT-1 and CHC-1 groups. Among these peaks, a 1738-m/z peak protein was identified as a fragment of complement component 4 (C4) and correlated significantly with serum C4a concentrations as determined by enzyme immunoassay. Serum C4a levels were also significantly higher in the PNALT-2 group compared to the CHC-2 group and healthy volunteers. Furthermore, in the PNALT-2 group, serum C4a levels negatively correlated with transaminase levels, but not with other biochemical tests, HCV core antigen levels, peripheral blood cell counts or serum hepatic fibrosis markers. This study indicates that host factors such as C4a not only differ between HCV carriers with PNALT and CHC, but that proteomic approaches could also contribute to the elucidation of factors in PNALT as more differences are discovered.

Indexed as

AdultAgedAged, 80 and overAlanine TransaminaseBiomarkersCarrier StateCase-Control StudiesCohort StudiesComplement C4aFemaleHepacivirusHepatitis C AntigensHepatitis C, ChronicHumansLiver CirrhosisMaleAlanine TransaminaseBiomarkersComplement C4aHepatitis C Antigensnucleocapsid protein, Hepatitis C virusRNA, ViralViral Core ProteinsC4 fragmentcomplement component C4ahepatitis C viruspersistent normal alanine amino transferaseserum proteomics

Identifiers

PMID22614103
PMCPMC3493081
OpenAlexW2151612053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.